Wednesday, November 18, 2026

Subscribe

NewsEdition AlgeriaAlgeria

Algeria seeks joint Maghreb response to pregabalin trafficking

After a record seizure of capsules, Algeria is calling for an African debate on pregabalin trafficking. Algiers wants to strengthen regional cooperation while preserving medical access to the treatment.

African delegation gathered in Vienna for institutional cooperation against the diversion of medicines

In Algiers, pregabalin is no longer merely a medicine being diverted. It has become a matter of police, health and customs cooperation across the Maghreb. After more than 10 million capsules were seized in August 2026, Algeria now wants to bring the debate before international drug-control mechanisms.

Algerian request put forward in Vienna

The initiative was presented at the 33rd meeting of Heads of National Drug Law Enforcement Agencies in Africa, known as HONLEA-Africa. The session took place in Vienna, Austria, from 8 to 11 September 2026.

At the close of the meeting, Tarek Kour, director-general of the National Office for the Fight Against Drugs and Drug Addiction, called for illicit trafficking and the non-medical use of pregabalin to be placed on the agenda of the next session. Algeria also wants to pave the way for the international scheduling of the molecule, which is currently absent from the lists of substances under global control. The ONLCDT statement on the Vienna meeting says the aim is to strengthen information-sharing between African countries.

This announcement does not mean that pregabalin is already internationally scheduled. It marks a first political step. The next HONLEA-Africa session will first have to consider the issue before it could be referred to the relevant United Nations bodies.

A legal medicine turned into a sought-after product on the black market

Pregabalin is prescribed for certain neuropathic pain conditions and to treat epilepsy. It is marketed under several names and is also available as a generic medicine. Its therapeutic status makes it difficult to control: the product first moves through legal pharmaceutical channels before being diverted through forged prescriptions, irregular dispensing or resale.

In 2018, the World Health Organization’s Expert Committee on Drug Dependence recommended that pregabalin should not be subject to international control. It did, however, call for it to remain under surveillance because of identified public-health risks. The WHO position published in 2019 recalls the balance sought between access to healthcare and the prevention of misuse.

International scheduling would change states’ obligations. It could strengthen the traceability of production, impose tighter controls on imports and facilitate cooperation against networks that exploit differences in regulation between countries.

August seizure prompted a shift in scale

On 20 August 2026, Algerian services announced the seizure of 10,402,700 pregabalin capsules dosed at 300 milligrams, as well as 33.4 kilograms of cocaine. The operation targeted a network described as international. Arrests took place simultaneously in Oran, Algiers, Blida, Tipasa and Tizi Ouzou.

The authorities said 25 suspects had been remanded in custody after appearing before the public prosecutor at the Sidi M’Hamed national criminal justice centre. A further 25 people were being sought at the time of the announcement, some of whom were believed to be abroad. These details relate to ongoing legal proceedings and do not prejudge the guilt of those accused. The figures released after the August operation were reported by several Algerian media outlets.

The case is part of a series of major seizures. For 2025, the ONLCDT reported that 43,413,420 psychotropic tablets had been seized. The total covers several substances and does not make it possible to isolate pregabalin alone. It measures the activity of the security services, but not the national level of consumption directly.

This distinction is essential. An increase in seizures may indicate an increase in trafficking. It may also reflect better intelligence, checks and cooperation between services. The available data therefore cannot, on its own, measure national prevalence.

A problem that extends beyond Algeria’s borders

Tunisia illustrates the regional dimension of the problem. In March 2025, Tunisian customs announced the seizure of 56,400 pregabalin tablets dosed at 300 milligrams in a lorry heading to Tunis. The official Tunisian customs portal said the tablets had been concealed in the vehicle.

A few months later, in October 2025, a network using foreign ambulances for international medical transport was dismantled in Ben Arous. About 92,000 pregabalin tablets and one kilogram of cocaine were seized, including from oxygen cylinders. The report on the Ben Arous operation shows the range of methods used by traffickers.

In May 2026, another case led to the seizure of 6,850 tablets in Sousse. These operations do not prove the existence of a single route, but they confirm the pressure on routes linking the Maghreb, Libya and Mediterranean markets.

Regional trafficking relies on several vulnerabilities. Networks exploit long borders, price differences and disparities between pharmaceutical laws. They can also use ordinary trade routes, including road transport, containers and some flows linked to health services.

Algeria’s challenge: control without restricting access to treatment

Algeria has already strengthened its national framework. Since 2021, pregabalin has been listed among psychotropic medicines carrying a proven risk of abuse. In 2024, a national classification of narcotic drugs, psychotropic substances and precursors further consolidated the applicable legal framework.

Control cannot, however, rely solely on arrests and seizures. It also concerns medical practices, pharmacies, wholesalers and prescription systems. The National Union of Community Pharmacists has for several years called for electronic prescriptions and a national register of psychotropic prescriptions. These tools would make it possible to identify repeated or forged prescriptions more quickly.

France has followed a comparable path. Since 24 May 2021, pregabalin prescriptions there have required a secure prescription form and have been limited to six months. The French National Agency for the Safety of Medicines said the measure was prompted by increasing misuse and prescription forgery.

For Algeria, the challenge is therefore to strike a balance. Tighter controls must reduce diversion without making it harder for people with epilepsy or chronic pain to access prescribed treatment.

An issue that is now regional and continental

By bringing the issue to HONLEA-Africa, Algiers is seeking to turn a national difficulty into a matter for African cooperation. This approach could facilitate the sharing of data on routes, clandestine laboratories, concealment methods and fraudulent prescribing practices.

What happens next will depend on whether the issue is formally included on the agenda of the 34th session. The positions of other African countries, the WHO and the United Nations Commission on Narcotic Drugs will then have to be assessed. In the meantime, the response will remain primarily national, even though distribution networks already cross several borders.

Automatic translation. Original French version

News quiz

Edition AlgeriaAlgeria: the news quiz for 11–15 November

5 questions